Matthew Kurian, MD, and Arturo Loaiza-Bonilla, MD, examine the rapid growth of AI in oncology and whether clinical validation can keep pace with innovation. They emphasize the need to distinguish industry hype from proven clinical applications while keeping patient care at the center of adoption decisions.
Transcript:
Dr. Kurian: There’s a lot in the news showing how quickly AI technologies are moving, and many tech leaders are concerned about the pace at which they’re being introduced. Do you think AI technologies being introduced in oncology are moving faster than we can adequately validate them?
Dr. Loaiza-Bonilla: I think there’s a lot of hype, but not a lot of substance, to be honest. I think people are saying, “Oh yeah, they’re going to replace oncologists,” and I’m like, sure, there are certain use cases, certain unique niche parts of the patient journey that could be replaced, and I’ll be happy to hand it over to an AI tool that is reliable.
But I don’t think we’re going too fast or any of that. I think that we as oncologists, and the patients themselves, want to see data before we even have adoption.
And I think that Silicon Valley and that whole X bubble is a very interesting bubble that I love to read from, learn from, and be part of. But I also have my reality check, which is the patient in front of me in my clinic in the community setting.
Dr. Kurian: Absolutely. Well, thanks, Dr. Artero, for letting me pick your brain about all the incoming developments at ESMO and in future AI technology. So thanks again.
Dr. Loaiza-Bonilla: Always. Anytime to talk to you, and I look forward to getting some updates from all those conferences.
Dr. Kurian: Yep. Absolutely.
